Solid Form Screening & Selection

Salts Screening

Salt formation is one of the primary solid-state approaches used to modify the physical properties of APIs. However, a major limitation within this approach is that the API must possess a suitable (basic or acidic) ionisable site. In comparison, co-crystals offer a different pathway, where any API regardless of acidic, basic or ionisable groups, could potentially be co-crystallized.   How can we help you? Investigate the formation of salts when the API itself is not sufficiently soluble or stable, or is

Read all

Solid Form Selection

For the selection of the optimal API, several solid forms may be available from one molecule. We provide an effective comparative programme that will lead to a better orientation and targeted selection of the optimum solid form of a certain pharmaceutical molecule with requested properties. In vitro bioequivalence studies, which are less variable, easier to control, and can predict the in vivo bioequivalence, saving time and cost Study of the dissolution rate profile of various forms Stability evaluation of va

Read all

Solvates/Hydrates Identification

In amorphous and crystalline forms, a solid drug may be anhydrous or a solvate/hydrate. When a solid form contains a solvent, it is known as a solvate. The presence of residual solvent may affect dramatically the crystalline structure of the solid depending on the type of intermolecular forces that the solvent may have with crystalline solid. When the solvent is water, it is termed a hydrate. Due to the frequent presence of water in the environment and its use in solvent blendings during the crystallization proces

Read all

Amorphous Dispersion

The amorphous form does not possess a defined order in its arrangement. Although the amorphous form is the most soluble form, it exhibits the lowest stability. Amorphous compounds are produced in the conditions when precipitation is kinetically faster than crystallisation and crystalline disorder caused by processing (i.e. milling or micronisation). It is also possible that more than one distinct amorphous phase may be formed from the same substance. In analogy with the phenomenon of crystalline polymorphism, this

Read all

Co-crystals Screening

Co-crystals are drug solids defined as multicomponent molecular crystals in which at least one of the compounds is an active pharmaceutical ingredient (API). Salts are considered different from co-crystals provided that they are crystals formed by ionic multicomponent. How can we help you? Investigate the formation of co-crystals when the API itself is not sufficiently soluble or stable, or is difficult to formulate or manufacture Possibility of discovering new patentable solid forms

Read all

Polymorph Screening

The knowledge of solid-state properties in an early stage of drug development helps to avoid manufacturing problems, to fine-tune the performance of drugs and provides space for innovations. By definition, every new crystal form is novel and not possible to predict how many different crystal forms can be prepared, how to prepare any crystal forms and the properties of any crystal forms as yet unknown. How can we help you? Identify under what conditions the polymorphs are formed Discover which forms are relev

Read all

© Copyright Polycrystalline SpA - All rights reserved - VAT IT02600021204 / powered by DibiWeb